Best for: Concentrated exposure to the 25 largest, most liquid biotech stocks . Strategy: Focuses on profitable blue-chip biotechs . Expense Ratio: 0.35% .
Strategy: Tracks the Nasdaq Biotechnology Index at a significantly lower price point . Expense Ratio: 0.19% .
AI responses may include mistakes. For financial advice, consult a professional. Learn more best biotech etf to buy now
💡 : Use the SEC EDGAR Database to review the latest prospectus and full risk disclosures for these ETFs before investing. If you'd like to narrow this down, tell me:
Your (e.g., comfortable with high volatility)? Your investment timeframe ? Best for: Concentrated exposure to the 25 largest,
Strategy: Market-cap weighted, dominated by giants like Vertex, Gilead, and Amgen . Expense Ratio: 0.44% . Best for: Low-cost core exposure .
Strategy: Actively managed by Cathie Wood's team, targeting "disruptive" innovation . Expense Ratio: 0.75% . Comparison of Key Metrics 1-Year Return Expense Ratio Small/Mid-Cap Equal Weight IBB Large-Cap Market Weighted SBIO Clinical Trial Breakthroughs IBBQ Nasdaq Biotech Index Data based on recent 2026 market reports . Strategy: Tracks the Nasdaq Biotechnology Index at a
Your (e.g., long-term stability vs. short-term growth)?